Safety of Zostavax?¡ªA cohort study in a managed care organization

详细信息    查看全文

• 作者：Roger Baxter ; Trung Nam Tran ; John Hansen ; Michael Emery ; Bruce Fireman ; Joan Bartlett ; Ned Lewis ; Patricia Saddier
• 关键词：Zoster ; Vaccine ; Shingles ; Varicella ; Safety
• 刊名：Vaccine
• 出版年：2012
• 出版时间：19 October, 2012
• 年：2012
• 卷：30
• 期：47
• 页码：6636-6641
• 全文大小：226 K

文摘

<h4 class=""h4"">Backgroundh4>Zostavax? is a live, attenuated varicella-zoster virus vaccine indicated for the prevention of herpes zoster (shingles). An observational post-licensure (Phase IV) study was conducted at Kaiser Permanente Northern California (KPNC), a US managed care organization, to assess the safety of zoster vaccine in people 60 years of age or older, vaccinated in routine medical care.<h4 class=""h4"">Methodsh4>

We performed a cohort study, comparing rates of clinical events resulting in hospitalizations or emergency department visits in a 42-day risk time period immediately following vaccination with rates in the same cohort in a subsequent comparison time period. The study data were reviewed and interpreted by an external safety review committee of 3 independent experts.<h4 class=""h4"">Resultsh4>

Approximately 29,000 people ¡Ý 60 years of age were vaccinated with zoster vaccine from July 2006 to November 2007. Of the 386 comparisons performed for the main analysis, 4 had an increased relative risk with a nominal p-value ¡Ü 0.05. After medical records review, the timing of these conditions and procedures was found to be often prior to vaccination, and no clear increase in health events was observed in the risk period following vaccination compared to later. Persons receiving zoster vaccine appeared to be in their optimal health at the time of vaccination, which led to an apparent protective effect of the vaccine for some health outcomes, due to the study design.<h4 class=""h4"">Conclusionsh4>

There was no evidence of a safety concern for zoster vaccine.